We were delighted to talk to Hyun C Chung (Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea) about the combination of lenvatinib plus pembrolizumab in the treatment of patients with advanced solid tumours (Clinical Trial Identifier: NCT03797326).
The abstract ‘LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the gastric cancer cohort.’ (ABSTRACT NUMBER: 230) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
- What is the rationale for the use of lenvatinib plus pembrolizumab in patients with advanced solid tumours? (0:05)
- Which patients are most likely to respond to this combination? (1:06)
Disclosures: Hyun C Chung discloses Grant/Research Support from Lilly, GSK, MSD, Merck-Serono, BMS/Ono, Taiho, Amgen, Beigene, Incyte and Zymework; Honoraria from Merck-Serono and Lilly; Consultation for Taiho, Celltrion, MSD, Lilly, BMS, Merck-Serono, Gloria, Beigene, Amgen and Zymework.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
Share this Video
Related Videos In Cancer Immunotherapy
Alessio Cortellini, ESMO Immuno-Oncology 2022: Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer
A joint analysis of patients receiving immune checkpoint inhibitor therapy was conducted using the OnCovid (NCT04393974) and ESMO CoCARE registries, this assessed SARS-CoV-2 outcomes in vaccinated and unvaccinated patients with cancer and whether prior immune-related adverse events affected these outcomes. In this touchIMMUNOLOGY interview, we spoke with Dr Alessio Cortellini (Fondazione Policlinico Universitario Campus Bio-Medico, […]
Marco Ruella, ASH 2021: Resistance Mechanisms to CAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (PART THREE)
Dr Marco Ruella (University of Pennsylvania, Philadelphia, PA, USA) discusses his presentation at the 63rd ASH Annual Meeting & Exposition on resistance mechanisms to CAR-T cells in patients with B-cell acute lymphoblastic leukemia. (PART THREE) Question What questions remain unanswered and what future studies are planned to assess resistance mechanisms to chimeric antigen receptor (CAR) […]
Marco Ruella, ASH 2021: Resistance Mechanisms to CAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (PART TWO)
Dr Marco Ruella (University of Pennsylvania, Philadelphia, PA, USA) discusses his presentation at the 63rd ASH Annual Meeting & Exposition on resistance mechanisms to CAR-T cells in patients with B-cell acute lymphoblastic leukemia. (PART TWO) Questions 1. Could you give us an overview of the mechanisms of chimeric antigen receptor (CAR) T-cell resistance? 00:15-05:28 2. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!